Morgan M. Goheen

Morgan M. Goheen

Auto-generated profile, based on publicly available information

Morgan M. Goheen

Section of Infectious Diseases, Yale School of Medicine , New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
JMJohn Muthii Muriuki
John Muthii Muriuki
AMAlexander J. Mentzer
Alexander J. Mentzer
GBGavin Band
Gavin Band
JGJames J. Gilchrist
James J. Gilchrist
TCTommy Carstensen
Tommy Carstensen
SASarah Atkinson
Sarah Atkinson
Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria parasites of iron essential for their growth.

30 October 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLSarah Lapidus
Sarah Lapidus
MGMorgan M Goheen
Morgan M Goheen
MSMouhamad Sy
Mouhamad Sy
ADAwa B Deme
Awa B Deme
INIbrahima Mbaye Ndiaye
Ibrahima Mbaye Ndiaye
ABAmy K Bei
Amy K Bei
Measuring malaria transmission intensity using the traditional entomological inoculation rate is difficult. Antibody responses to mosquito salivary proteins like SG6 have been used as biomarkers of exposure to Anopheles mosquito bites. Here, we investigate four mosquito salivary proteins as potential biomarkers of human exposure to mosquitoes infected with P. falciparum: mosGILT, SAMSP1, AgSAP, and AgTRIO. We tested population-level human immune responses in longitudinal and cross-sectional plasma from individuals with known P. falciparum infection from low and moderate transmission areas in Senegal using a multiplexed magnetic bead-based assay. AgSAP and AgTRIO were the best indicators of recent exposure to infected mosquitoes. Antibody responses to AgSAP, in a moderate endemic area, and to AgTRIO in both low and moderate endemic areas, were significantly higher than responses in a healthy non-endemic control cohort (p-values = 0.0245, 0.0064, and <0.0001 respectively). No antibody responses significantly differed between the low and moderate transmission area, or between equivalent groups during and outside the malaria transmission seasons. For AgSAP and AgTRIO, reactivity peaked 2-4 weeks after clinical P. falciparum infection and declined 3 months after infection. Reactivity to AgSAP and AgTRIO peaked after infection, with no differences between transmission seasons within region or between low and moderate transmission regions. This suggests that reactivity reflects exposure to infectious mosquitoes or recent bites rather than general mosquito exposure. Kinetics suggest reactivity is relatively short-lived. AgSAP and AgTRIO are promising candidates to incorporate into multiplexed assays for serosurveillance of population-level changes in P. falciparum-infected mosquito exposure.

6 January 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
FJFatou Joof
Fatou Joof
MGMorgan M. Goheen
Morgan M. Goheen
CCCarla Cerami
Carla Cerami
Artemisinin combination therapies are the current frontline therapy for falciparum malaria. Artemisinin is activated by heme iron, and the consequent production of reactive oxygen species and carbon-centered radicals results in rapid parasite clearance. Red blood cells (RBCs) from anemic iron-deficient individuals have decreased levels of heme, and such deficiencies are highly prevalent among children and pregnant women in malaria-endemic countries. We, therefore, investigated the possibility that host anemia could impair artemisinin activity and alter the drug sensitivity of artemisinin-resistant strains of Plasmodium falciparum. We collected RBCs from anemic (n = 35) and nonanemic (n = 11) Gambian children between the ages of 2 and 24 months. Parasites grown in RBCs from both groups were assessed in vitro using the ring-stage survival assay with artemisinin-resistant and artemisinin-sensitive strains of P. falciparum. No differences were found in artemisinin sensitivity (P > 0.05), and there was no correlation between artemisinin activity and host hemoglobin levels. Standard antimalarial drug activity assays for representatives of the major classes of antimalarial drugs found no differences in the IC50 values against P. falciparum between anemic and nonanemic RBCs. We conclude that host anemia does not influence artemisinin activity.

22 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SLSarah Lapidus
Sarah Lapidus
MGMorgan M. Goheen
Morgan M. Goheen
MSMouhamad Sy
Mouhamad Sy
ADAwa B. Deme
Awa B. Deme
INIbrahima Mbaye Ndiaye
Ibrahima Mbaye Ndiaye
ABAmy K. Bei
Amy K. Bei
Background: Measuring malaria transmission intensity using the traditional entomological inoculation rate is difficult. Antibody responses to mosquito salivary proteins such as SG6 have previously been used as biomarkers of exposure to Anopheles mosquito bites. Here, we investigate four mosquito salivary proteins as potential biomarkers of human exposure to mosquitoes infected with P. falciparum : mosGILT, SAMSP1, AgSAP, and AgTRIO. Methods: We tested population-level human immune responses in longitudinal and cross-sectional plasma samples from individuals with known P. falciparum infection from low and moderate transmission areas in Senegal using a multiplexed magnetic bead-based assay. Results: AgSAP and AgTRIO were the best indicators of recent exposure to infected mosquitoes. Antibody responses to AgSAP, in a moderate endemic area, and to AgTRIO in both low and moderate endemic areas, were significantly higher than responses in a healthy non-endemic control cohort (p-values = 0.0245, 0.0064, and <0.0001 respectively). No antibody responses significantly differed between the low and moderate transmission area, or between equivalent groups during and outside the malaria transmission seasons. For AgSAP and AgTRIO, reactivity peaked 2-4 weeks after clinical P. falciparum infection and declined 3 months after infection. Discussion: Reactivity to both AgSAP and AgTRIO peaked after infection and did not differ seasonally nor between areas of low and moderate transmission, suggesting reactivity is likely reflective of exposure to infectious mosquitos or recent biting rather than general mosquito exposure. Kinetics suggest reactivity is relatively short-lived. AgSAP and AgTRIO are promising candidates to incorporate into multiplexed assays for serosurveillance of population-level changes in P. falciparum -infected mosquito exposure.

17 November 2025 in bioRxiv
Verified
Preprint
Open access
MGMorgan M. Goheen
Morgan M. Goheen
AOAlessandra Orfanó
Alessandra Orfanó
SDS. Rodrigue Dah
S. Rodrigue Dah
BFBrian D. Foy
Brian D. Foy
DBDoug E. Brackney
Doug E. Brackney
SPSunil Parikh
Sunil Parikh
The World Health Organization’s recommendations regarding the use of antimalarials for the prevention of malaria in endemic areas have greatly expanded, allowing more flexibility in the demographic groups and regions where chemoprevention and mass treatment are acceptable. An overlooked aspect of expanding human population-level drug exposure is the downstream impact of ingested drug on the mosquito vector. Data suggest both infected and uninfected Anopheles mosquitoes re-feed often with ≥4 blood meals during their lifespan. This provides repeated opportunities for mosquitoes to ingest drug via bloodmeals taken from people with antimalarials in the bloodstream and raises questions as to whether exposure may impact the mosquito itself, and/or parasites developing within the infected mosquito. We investigated the impact of exposure to physiologic levels of commonly used long-acting human antimalarials in the Anopheles mosquito via drug-spiked blood feeds. We did not observe any significant differences in mosquito feeding, behavior, fertility, or viability after ingestion of amodiaquine, desethylamodiaquine, piperaquine, and sulfadoxine-pyrimethamine in either lab-reared An. gambiae or field-derived An. coluzzii mosquitoes. Interrogating drug distribution within mosquitoes utilizing LC-MS/MS, desethylamodiaquine, the longer-acting active metabolite of amodiaquine, was fed at 2 concentrations (1/2X and 2X C max ) with drug subsequently detected in a dose-dependent manner in pooled whole mosquitoes, midguts and hemolymph. This was significant for whole mosquitoes harvested at 24hrs and 120hrs, and midguts harvested at 24hrs. Between 24 to 120 hrs, drug decreased in midguts but increased in hemolymph. Our results show biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion. These studies lay the foundation for future work to assess the impact of vector-stage antimalarial drug exposure on parasite progression throughout development in the mosquito, which could in turn have important implications for transmission dynamics and drug resistance spread. Author summary: Drug resistance to first-line antimalarials has emerged in multiple African countries. A better understanding of antimalarial drug resistance emergence and spread is critical in preventing further morbidity and mortality. Millions regularly receive antimalarials for prophylaxis and mass treatment that are purposefully long-acting. Anopheles mosquitoes re-feed frequently, and these malaria vectors (both infected and uninfected) routinely feed on people whose blood contains these long-acting antimalarials. Parasites take approximately 10 days to develop within the mosquito. There is published precedent that several antimalarials can act upon vector-stage parasites, yet any potential impact of antimalarials on mosquitoes and/or parasites developing within has been largely overlooked. We questioned whether antimalarials ingested in mosquito bloodmeals could influence parasite development and drug resistance selection. As initial investigations, we exposed uninfected Anopheles mosquitoes to commonly used long-acting antimalarials via drug-spiked bloodmeals, mimicking predicted physiologic drug exposure. Investigated drugs did not impact mosquito viability. However, mass spectrometry confirmed drug absorption in whole mosquitoes, as well as within midguts and circulatory fluid, several days after feeding, demonstrating that mosquitoes can ingest key drugs without suffering fitness costs, and these drugs can persist in mosquitoes. This highlights the potential for antimalarials to impact parasite development and drug resistance selection within the mosquito.

15 June 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
MGMorgan M Goheen
Morgan M Goheen
AOAlessandra Orfanó
Alessandra Orfanó
SDSié Rodrigue Dah
Sié Rodrigue Dah
BFBrian D Foy
Brian D Foy
DBDoug E Brackney
Doug E Brackney
SPSunil Parikh
Sunil Parikh
Background: The World Health Organization's recommendations for antimalarial chemoprevention and mass treatment use in endemic areas have greatly expanded, allowing more flexibility in demographic groups and regions targeted. An overlooked aspect of expanding human population-level drug exposure is the downstream impact of a drug on the vector. Anopheles mosquitoes refeed often with ≥ 4 bloodmeals during their lifespan. This provides repeated opportunities for mosquitoes to ingest a drug via bloodmeals taken from people with antimalarials in the bloodstream and raises questions as to the drug’s impact on mosquitoes. Methods: We supplemented bloodmeals with physiologic levels of long-acting antimalarials to assess drug exposure impact on Anopheles mosquito fitness and determine drug absorption extent. Results: We did not observe any significant differences in mosquito feeding, behavior, fecundity, or viability after amodiaquine, desethylamodiaquine, piperaquine, and sulfadoxine-pyrimethamine ingestion in laboratory-reared Anopheles gambiae or field-derived Anopheles coluzzii mosquitoes. Interrogating drug distribution within mosquitoes utilizing liquid chromatography-tandem mass spectrometry, desethylamodiaquine, amodiaquine's longer-acting active metabolite, was fed at half and twice reported Cmax concentrations; the drug was dose-dependently detected in pooled whole mosquitoes, midguts, and hemolymph. This was statistically significant for whole mosquitoes harvested at 24 and 120 hours, and midguts harvested at 24 hours. Between 24 and 120 hours, the drug decreased in midguts but increased in hemolymph. Conclusions: We show sustained biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion without fitness costs. These studies provide a foundation to next assess vector-stage antimalarial drug exposure impact on parasite development in infected mosquitoes, which could in turn have implications for transmission dynamics and drug resistance spread.